tiprankstipranks
BioAtla (BCAB)
NASDAQ:BCAB
US Market

BioAtla (BCAB) Income Statement

170 Followers

BioAtla Income Statement

Last quarter (Q4 2023), BioAtla's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, BioAtla's net income was $-26.93M. See BioAtla’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
---$ 300.00K$ 429.00K$ 5.20M
Cost of Revenue
------
Gross Profit
---$ 300.00K--
Operating Expense
$ 129.69M$ 129.69M$ 108.14M$ 96.69M$ 30.53M$ 33.47M
Operating Income
$ -129.69M$ -129.69M$ -108.14M$ -96.69M$ -30.10M$ -28.27M
Net Non Operating Interest Income Expense
$ 6.31M$ 6.31M$ 1.65M$ 347.00K$ -1.29M$ -1.50M
Other Income Expense
$ 87.00K$ 87.00K$ -10.00K$ -941.00K$ -4.46M$ -85.00K
Pretax Income
$ -123.46M$ -123.46M$ -106.48M$ -95.40M$ -35.85M$ -29.86M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -123.46M$ -123.46M$ -106.48M$ -95.40M$ -35.85M$ -29.79M
Basic EPS
$ -2.59$ -2.58$ -2.74$ -2.76$ -3.19$ -1.30
Diluted EPS
$ -2.59$ -2.58$ -2.74$ -2.76$ -3.19$ -1.30
Basic Average Shares
$ 191.11M$ 47.78M$ 38.93M$ 34.56M$ 8.43M$ 21.59M
Diluted Average Shares
$ 191.11M$ 47.78M$ 38.93M$ 34.56M$ 8.43M$ 21.59M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 129.69M$ 129.69M$ 108.14M$ 96.69M$ 30.53M$ 33.47M
Net Income From Continuing And Discontinued Operation
$ -123.46M$ -123.46M$ -106.48M$ -95.40M$ -35.85M$ -29.79M
Normalized Income
$ -75.84M$ -97.53M--$ -31.39M$ -29.73M
Interest Expense
----$ 1.39M$ 1.63M
EBIT
$ -124.94M$ -123.46M$ -106.48M$ -95.75M$ -34.46M$ -28.23M
EBITDA
$ -123.72M$ -122.24M$ -105.28M$ -94.42M$ -33.46M$ -27.36M
Currency in USD

BioAtla Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis